Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation☆
Henrik ten-Freyhaus(University of Cologne), Stephan Rosenkranz(University of Cologne), Michael Huntgeburth(University of Cologne), Mohamed M. Bekhite(Jena University Hospital), Henning Sauer(Justus-Liebig-Universität Gießen), Maria Wartenberg(Jena University Hospital), Alessandra Baumer, Marius Vantler(University of Cologne), Kirstin Wingler(Vasopharm (Germany)), J Schnitker(University of Cologne)
Cited by 253
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial
|European Heart Journal|2015|246
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
|The Journal of Heart and Lung Transplantation|2020|207
Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension
|Arteriosclerosis Thrombosis and Vascular Biology|2012|124